{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:49:50Z","timestamp":1784224190035,"version":"3.55.0"},"reference-count":28,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022661","name":"European Brain Council","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100022661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MRC","award":["MR\/N028767\/1"],"award-info":[{"award-number":["MR\/N028767\/1"]}]},{"name":"Reata pharmaceuticals","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,8,13]]},"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study aims to assess the patient-reported benefits and the costs of coordinated care and multidisciplinary care at specialist ataxia centres (SACs) in the UK compared with care delivered in standard neurological clinics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>A patient survey was distributed between March and May 2019 to patients with ataxia or carers of patients with ataxia through the Charity Ataxia UK\u2019s mailing list, website, magazine and social media to gather information about the diagnosis, management of the ataxias in SAC and non-specialist settings, utilisation of various healthcare services and patients\u2019 satisfaction. We compared mean resource use for each contact type and health service costs per patient, stratifying patients by whether they were currently attending a SAC or never attended one.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Secondary care including SACs and general neurology clinics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>We had 277 participants in the survey, aged 16 years old and over, diagnosed with ataxia and living in the UK.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Primary outcome measures<\/jats:title>\n                  <jats:p>Patient experience and perception of the two healthcare services settings, patient level of satisfaction, difference in healthcare services use and costs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Patients gave positive feedback about the role of SAC in understanding their condition (96.8% of SAC group), in coordinating referrals to other healthcare specialists (86.6%), and in offering opportunities to take part in research studies (85.2%). Participants who attended a SAC reported a better management of their symptoms and a more personalised care received compared with participants who never attended a SAC (p&lt;0.001). Costs were not significantly different in between those attending a SAC and those who did not. We identified some barriers for patients in accessing the SACs, and some gaps in the care provided, for which we made some recommendations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study provides useful information about ataxia patient care pathways in the UK. Overall, the results showed significantly higher patient satisfaction in SAC compared with non-SAC, at similar costs. The findings can be used to inform policy recommendations on how to improve treatment and care for people with these very rare and complex neurological diseases. Improving access to SAC for patients across the UK is one key policy recommendation of this study.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-084865","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T02:35:42Z","timestamp":1725590142000},"page":"e084865","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of specialist ataxia centres with non-specialist services in terms of treatment, care, health services resource utilisation and costs in the UK using patient-reported data"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2092-5073","authenticated-orcid":false,"given":"Julie","family":"Vallortigara","sequence":"first","affiliation":[{"name":"Ataxia Centre, Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Greenfield","sequence":"additional","affiliation":[{"name":"Ataxia UK, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Hunt","sequence":"additional","affiliation":[{"name":"Ataxia UK, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Booth","sequence":"additional","affiliation":[{"name":"Ataxia Centre, Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5828-3563","authenticated-orcid":false,"given":"Stephen","family":"Morris","sequence":"additional","affiliation":[{"name":"University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Giunti","sequence":"additional","affiliation":[{"name":"Ataxia Centre, Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"2025101810084171000_14.9.e084865.1","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1212\/CON.0000000000000362","article-title":"Ataxia","volume":"22","author":"Ashizawa","year":"2016","journal-title":"Continuum (Mount Lawley)"},{"key":"2025101810084171000_14.9.e084865.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaitpost.2017.11.024"},{"key":"2025101810084171000_14.9.e084865.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117082"},{"key":"2025101810084171000_14.9.e084865.4","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.neurol.2016.07.003","article-title":"Movement disorders in mitochondrial diseases","volume":"172","author":"Tranchant","year":"2016","journal-title":"Rev Neurol (Paris)"},{"key":"2025101810084171000_14.9.e084865.5","first-page":"6","article-title":"Progressive late-onset cerebellar ataxia","volume":"7","author":"Wardle","year":"2007","journal-title":"Adv Clin Neurosci Rehabil"},{"key":"2025101810084171000_14.9.e084865.6","first-page":"80","article-title":"Prevalence of ataxia in children: a systematic review","volume":"82","author":"Musselman","year":"2014","journal-title":"Neurol (ECronicon)"},{"key":"2025101810084171000_14.9.e084865.7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.14.7452"},{"key":"2025101810084171000_14.9.e084865.8","doi-asserted-by":"crossref","first-page":"932","DOI":"10.12968\/bjon.2006.15.17.21908","article-title":"Centres of excellence for the care of people with progressive ataxias","volume":"15","author":"Greenfield","year":"2006","journal-title":"Br J Nurs"},{"key":"2025101810084171000_14.9.e084865.9","doi-asserted-by":"crossref","first-page":"544","DOI":"10.12968\/bjnn.2008.4.11.31698","article-title":"Centres of excellence for the care of people with progressive ataxias","volume":"4","author":"Greenfield","year":"2008","journal-title":"Br J Neurosci Nurs"},{"key":"2025101810084171000_14.9.e084865.10","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-019-1013-9","article-title":"Guidelines on the diagnosis and management of the progressive ataxias","volume":"14","author":"de Silva","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"2025101810084171000_14.9.e084865.11","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3325\/cmj.2019.60.156","article-title":"Toward earlier diagnosis and treatment of rare neurological disorders: the value of coordinated care and specialist centers","volume":"60","author":"Giunti","year":"2019","journal-title":"Croat Med J"},{"key":"2025101810084171000_14.9.e084865.12","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-014-0184-7","article-title":"Consensus clinical management guidelines for Friedreich ataxia","volume":"9","author":"Corben","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"2025101810084171000_14.9.e084865.13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/acn3.51266","article-title":"Lower urinary tract and bowel dysfunction in spinocerebellar ataxias","volume":"8","author":"Afonso Ribeiro","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"2025101810084171000_14.9.e084865.14","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-017-0709-y","article-title":"Urinary, bowel and sexual symptoms in a cohort of patients with Friedreich\u2019s ataxia","volume":"12","author":"Lad","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"2025101810084171000_14.9.e084865.15","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-021-01236-9"},{"key":"2025101810084171000_14.9.e084865.16","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2018-002096"},{"key":"2025101810084171000_14.9.e084865.17","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-023-02907-y","article-title":"Patient pathways for rare diseases in Europe: ataxia as an example","volume":"18","author":"Vallortigara","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"2025101810084171000_14.9.e084865.18","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-023-02971-4","article-title":"Impact of specialist ataxia centres on health service resource utilisation and costs across Europe: cross-sectional survey","volume":"18","author":"Morris","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"2025101810084171000_14.9.e084865.19","article-title":"Symptom burden of people with progressive ataxia, and its wider impact on their friends and relatives: a cross-sectional study","volume":"3","author":"Lowit","year":"2021","journal-title":"AMRC Open Res"},{"key":"2025101810084171000_14.9.e084865.20","unstructured":"NICE process and methods [PMG36] . Economic evaluation, 2022. Available: https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/economic-evaluation-2#evidence-on-resource-use-and-costs"},{"key":"2025101810084171000_14.9.e084865.21","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40273-017-0512-6","article-title":"How to appropriately extrapolate costs and utilities in cost-effectiveness analysis","volume":"35","author":"Bojke","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"2025101810084171000_14.9.e084865.22","unstructured":"Jones K , Burns A . Unit Costs of Health and Social Care 2021. University of Kent, Canterbury: Personal Social Services Research Unit, 2021."},{"key":"2025101810084171000_14.9.e084865.23","unstructured":"StataCorp . Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC, 2017."},{"key":"2025101810084171000_14.9.e084865.24","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1093\/brain\/awad009","article-title":"Functional genomics provide key insights to improve the diagnostic yield of hereditary ataxia","volume":"146","author":"Chen","year":"2023","journal-title":"Brain (Bacau)"},{"key":"2025101810084171000_14.9.e084865.25","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X16666180917105033"},{"key":"2025101810084171000_14.9.e084865.26","unstructured":"ataxia . Oxford Adult\u2019s & Children\u2019s Centre, Available: https:\/\/www.ataxia.org.uk\/newly-diagnosed\/specialist-ataxia-centres\/oxford-childrens-adults-centre\/"},{"key":"2025101810084171000_14.9.e084865.27","unstructured":"UK Rare Disease . The Rare Reality \u2013 An Insight into the Patient and Family Experience of Rare Disease, 2016. Available: www.gov.uk\/government\/publications\/uk-rare-diseases-framework\/the-uk-rare-diseases-framework"},{"key":"2025101810084171000_14.9.e084865.28","unstructured":"Department of Health and Social Care . GOV.UK; The UK rare diseases framework, 2021. Available: https:\/\/assets.publishing.service.gov.uk\/media\/5ff781138fa8f5640335254e\/the-UK-rare-diseases-framework.pdf"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-084865","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T17:08:51Z","timestamp":1760807331000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-084865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":28,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,5]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1136\/bmjopen-2024-084865"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-084865","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]}}}